4575 CanBas
- 509
- +20+4.09%
CanBas News
CanBas: Company presentation materials 2024/5 3rd quarter financial results reflection version
CanBas: Quarterly Report - 25th Quarter 3rd Quarter (2024/01/01 to 2024/03/31)
CanBas: Confirmation letter
CanBas: Notice regarding the recording of non-operating profit and loss
CanBas: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/6 [Japanese GAAP] (unconsolidated)
CanBas: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clauses through Third-Party Allotment
Canvas: Change Report (Stock Certificates Subject to Special Cases, etc.)
CanBas: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clauses through Third-Party Allotment
Canvas: Change Report (Stock Certificates Subject to Special Cases, etc.)
Canvas: Company Presentation Materials March 2024 Edition
Canvas: Notice regarding the monthly exercise status of stock acquisition rights with price correction clauses exercised through third-party allotment
Canvas: Notice of publication in a journal on CBP501 clinical phase 2 trial results (progress of disclosure information)
Canvas: Explanatory materials on business plans and growth potential (2024/2 updated version)
Canvas: Announcement of the start of discussions with the EMA for the start of the CBP501 European Clinical Phase 3 trial
Canvas: Notice of publication in a journal on CBP501 clinical phase 2 trial results
Canvas: Change Report (Stock Certificates Subject to Special Cases, etc.)
CanBas: Documents on the “2nd Quarter Financial Results Briefing for the Fiscal Year Ending 2024/6” held on 2024/2/15
CanBas: Supplementary Q&A announcement on “CBP501 Next Phase Clinical Trial Schedule in the US and Clinical Phase 3 Clinical Trial Preparation in Europe” published on 2/9
canvas: confirmation
Canvas: Quarterly Report - 25th Quarter 2nd Quarter (2023/10/01 to 2023/12/31)
Analysis
Price Target
No Data
